Literature DB >> 8086331

Peripheral factors in the management of congestive heart failure.

L Demopoulos1, T H LeJemtel.   

Abstract

Maladaptive changes in the periphery largely account for the symptomatology of patients with congestive heart failure (CHF). A decline in the systolic function of the left ventricle precipitates activation of neural and humoral systems to provide circulatory support. These include sympathetic release of norepinephrine, increases in angiotensin II, elevated levels of circulating arginine vasopressin, and impairment of the counterregulatory function of atrial natriuretic peptide. The resultant circulatory changes are ultimately responsible for the declining function of the peripheral vasculature and skeletal muscles of patients with CHF. In the peripheral vasculature, impaired vasodilatory capacity results from excess vessel wall stiffness, endothelial dysfunction, and structural abnormalities. The skeletal muscles develop poor aerobic capacity as a result of a change in predominant fiber type and excess reliance on glycolytic metabolic pathways. Physical deconditioning induced by symptoms tends to further promote these peripheral changes. Therapeutic interventions with symptomatic and prognostic benefits have essentially been targeted at the periphery. Angiotensin converting enzyme inhibitors may act by normalizing electrolyte and water balance, improving vascular endothelial function, and reversing structural changes in peripheral vessels. Exercise training appears to exert its benefit at the level of the vascular endothelium. Advances in the therapy of CHF depend on a greater understanding of changes in the periphery.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086331     DOI: 10.1007/bf00877092

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  63 in total

1.  Exercise tolerance in congestive heart failure. Role of cardiac function, peripheral blood flow, and muscle metabolism and effect of treatment.

Authors:  B M Massie
Journal:  Am J Med       Date:  1988-03-11       Impact factor: 4.965

2.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.

Authors:  M A Konstam; M F Rousseau; M W Kronenberg; J E Udelson; J Melin; D Stewart; N Dolan; T R Edens; S Ahn; D Kinan
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

3.  Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

4.  Endothelial dysfunction of hindquarter resistance vessels in experimental heart failure.

Authors:  H Drexler; W Lu
Journal:  Am J Physiol       Date:  1992-06

5.  Heart failure depresses endothelium-dependent responses in canine femoral artery.

Authors:  L Kaiser; R C Spickard; N B Olivier
Journal:  Am J Physiol       Date:  1989-04

6.  31P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failure.

Authors:  B M Massie; M Conway; R Yonge; S Frostick; P Sleight; J Ledingham; G Radda; B Rajagopalan
Journal:  Am J Cardiol       Date:  1987-08-01       Impact factor: 2.778

7.  Enhanced maximal metabolic vasodilatation in the dominant forearms of tennis players.

Authors:  L I Sinoway; T I Musch; J R Minotti; R Zelis
Journal:  J Appl Physiol (1985)       Date:  1986-08

8.  Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failure.

Authors:  D M Mancini; L Davis; J P Wexler; B Chadwick; T H LeJemtel
Journal:  J Am Coll Cardiol       Date:  1987-10       Impact factor: 24.094

Review 9.  Endocrine mechanisms in congestive cardiac failure. Renin, aldosterone and atrial natriuretic hormone.

Authors:  J H Laragh
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Lactate production during maximal and submaximal exercise in patients with chronic heart failure.

Authors:  K T Weber; J S Janicki
Journal:  J Am Coll Cardiol       Date:  1985-10       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.